• Contact
  • Careers
    •
  • About us
  • Who we are
  • Mission, vision and values
  • Management board
  • Supervisory board
  • Scientific advisory board
  • Partnering
    •
  • Our technology
  • What we are targeting
  • Histones explained
  • M6229
  • Next Generation M6229
    •
  • Pipeline
  • Pipeline
  • Clinical trials
  • IP position
    •
  • Sepsis & septic shock
  • What is sepsis?
  • Current treatment
  • Health impact
  • Economic impact
    •
  • News
  • About us
  • Who we are
  • Mission, vision and values
  • Management board
  • Supervisory board
  • Scientific advisory board
  • Partnering
    •
  • Our technology
  • What we are targeting
  • Histones explained
  • M6229
  • Next Generation M6229
    •
  • Pipeline
  • Pipeline
  • Clinical trials
  • IP position
    •
  • Sepsis & septic shock
  • What is sepsis?
  • Current treatment
  • Health impact
  • Economic impact
    •
  • News
  • Contact
  • Careers
    •
    IP Position

    IP Position

    Matisse Pharmaceuticals BV has obtained a worldwide exclusive and transferable license from Maastricht University (MU) and Maastricht University Medical Centre (MUMC+) for commercializing M6229 , use of M6229 in transplant failure and Next Generation M6229. Matisse has a solid patent protection on its developments and complete freedom to operate.